SMITHKLINE BEECHAM TAGAMET HB WILL CARRY LOWER PER-DOSE PRICE THAN J&J MERCK's PEPCID AC; Rx-TO-OTC SWITCH ANTACID PRODUCT WILL BE AVAILABLE IN AUTUMN
SmithKline Beecham's Tagamet HB will be marketed at a lower per-dose price than competitor J&J Merck's Pepcid AC, SmithKline Beecham Consumer Healthcare-North America President Jack Ziegler indicated during a June 20 teleconference announcing FDA approval of the new over-the-counter version of cimetidine. "Our expectation is that the consumer will find Tagamet pricing...lower than Pepcid on a per dose basis" but higher than Maalox and Mylanta, Ziegler said. SmithKline's OTC cimetidine was cleared by FDA on June 19 for symptomatic relief of heartburn, acid indigestion and sour stomach.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth